SEC Form SC 13G filed by Bausch Health Companies Inc.

4/23/21 5:16:55 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BHC alert in real time by email

SC 13G 1 Schedule13gmeruelo.txt SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment ___)* Bausch Health Companies Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 071734107 (CUSIP Number) April 5, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [ X ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person?s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be ?filed? for the purpose of Section 18 of the Securities Exchange Act of 1934 (?Act?) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 1. NAME OF REPORTING PERSON Alex Meruelo 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ? (b) ? 3. SEC USE ONLY 4. CITIZENSHIP OF PLACE OF ORGANIZATION United States of America NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 19,604,777 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 19,604,777 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 19,604,777 10. CHECK BOX IF THE AGGREGATE AMOUNT OF ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ? 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.51% 12. TYPE OF REPORTING PERSON IN Item 1(a). Name of Issuer Bausch Health Companies Inc. Item 1(b). Address of Issuer?s Principal Executive Offices 2150 St. Elzear Blvd. West, Laval, Quebec, Canada H7L 4A8 Item 2(a). Name of Person Filing This Statement is filed on behalf of Alex Meruelo (?Mr. Meruelo?). Mr. Meruelo is the sole trustee of Alex Meruelo Living Trust dated August 6, 1996 (?the ?Trust?) and the sole shareholder of the Monterey Insurance Company, Inc., a Utah corporation (?Monterey?). Item 2(b). Address of Principal Business Office or, if None, Residence: The address of the principal business office of Mr. Meruelo and the Trust is 2500 E. Second Street, Reno, Nevada 89595, Attention: Management Office. The address and principal business office of Monterey is 2750 Rasmussen Road, Suite H-105 Park City, Utah 84098. Item 2(c). Citizenship: Mr. Meruelo is a citizen of the United States of America. Item2(d). Title of Class of Securities: Common Shares, no par value (the ?Shares?). The Shares also consist of options to purchase Shares which are exercisable in sixty days or less. Item 2(e). CUSIP Number: 071734107 Item 3. If This Statement is Filed Pursuant to ??240.13d- 1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a: This Item 3 is not applicable. Item4. Ownership: Item 4(a). Amount Beneficially Owned: As of April 16, 2021, because Mr. Meruelo is the sole trustee of the Trust and sole shareholder of Monterey, and because of the family relationships described below, Mr. Meruelo may be deemed the beneficial owner of 19,604,777 Shares. This amount consists of (i) 18,096,977 Shares held for the account of the Trust, including 11,399,000 Shares underlying call options currently exercisable, (ii) 1,236,900 Shares held for the account of Monterey, including 458,000 Shares underlying call options currently exercisable, (iii) 175,000 Shares in the account of Liset Meruelo, the spouse of Mr. Meruelo, (iv) 5,000 Shares in the joint account of Liset Meruelo and her mother, (v) 37,400 Shares in the account of Alexander Meruelo, an adult child of Mr. Meruelo, including 21,500 Shares underlying call options currently exercisable, (vi) 31,000 Shares in the account of Alexis Meruelo, an adult child of Mr. Meruelo and (vii) 22,500 Shares in the account of Lisette Meruelo, an adult child of Mr. Meruelo. Mr. Meruelo disclaims? ownership of the Shares held in the accounts of Liset Meruelo and her mother, and his adult children. Item 4(b). Percent of Class: As of April 14, 2021, Mr. Meruelo may be deemed the beneficial owner of approximately 5.51% of Shares outstanding. (There were 355,619,826 Shares outstanding as of February 18, 2021, according to the Issuer?s Form 10-K for the fiscal year ended December 31, 2020. Item 4(c). Number of Shares as to which such person has: (i) Sole power to vote or direct the vote: (ii) Shared Power to vote or direct the vote: 19,604,777 (iii) Sole power to dispose or direct the disposition of: (iv) Shared power to dispose or direct the disposition of: 19,604,777 Item 5. Ownership of Five Percent or Less of a Class: This Item 5 is not applicable Item 6. Ownership of More than Five Percent on Behalf of Another Person: As discussed in item 4(a) above, certain securities reported are held by or on behalf of persons other than the reporting person, which other persons have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. The reporting person disclaims beneficial ownership of Shares except to the extent the reporting person actually has or shares voting power or investment power with respect to such Shares and the reporting thereof shall not be construed as an admission that the reporting person is a beneficial owner of such Shares. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person This Item 7 is not applicable. Item 8. Identification and Classification of Members of the Group. This Item 8 is not applicable. Item 9. Notice of Dissolution of Group: This Item 9 is not applicable. Item 10. Certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?240.14a-11. SIGNATURE After reasonable inquiry and to the best of each of the undersigned?s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. /s/ Alex Meruelo Alex Meruelo SCHEDULE 13G CUSIP No. 071734107 {WLMLAW W0010741.DOC} 1 1

Get the next $BHC alert in real time by email

Recent Analyst Ratings for

$BHC

Date	Price Target	Rating	Analyst
8/2/2024	$9.00 → $3.00	Neutral → Underweight	Piper Sandler
7/10/2024	$8.00	Mkt Perform	Raymond James
9/20/2023	$9.00 → $16.00	Hold → Buy	Jefferies
6/16/2023		Outperform → Market Perform	TD Cowen
7/29/2022		Buy → Hold	Truist
7/29/2022	$12.00 → $5.00	Outperform → Sector Perform	RBC Capital Mkts
7/28/2022		Overweight → Neutral	JP Morgan
6/13/2022	$12.00	Overweight	JP Morgan

More analyst ratings

SEC Form SC 13G filed by Bausch Health Companies Inc.

Chat with this insight

Recent Analyst Ratings for
$BHC

$BHC
SEC Filings

Bausch Health Companies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form DEFA14A filed by Bausch Health Companies Inc.

SEC Form CERT filed by Bausch Health Companies Inc.

$BHC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Bausch Health downgraded by Piper Sandler with a new price target

Raymond James initiated coverage on Bausch Health with a new price target

Bausch Health upgraded by Jefferies with a new price target

$BHC
Press Releases

Fastest customizable press release news feed in the world

Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program

Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day

$BHC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Wechsler Amy B was granted 1,062 shares, increasing direct ownership by 0.51% to 209,008 units (SEC Form 4)

Director Icahn Brett was granted 5,119 shares, increasing direct ownership by 3% to 161,899 units (SEC Form 4)

Director Paulson John was granted 9,659 shares, increasing direct ownership by 4% to 277,708 units (SEC Form 4)

$BHC
Financials

Live finance-specific insights

Bausch Health Announces Third Quarter 2024 Results

Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

Bausch Health Announces Second Quarter 2024 Results

$BHC
Leadership Updates

Live Leadership Updates

$BHC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Bausch Health Appoints New Chief Medical Officer and Head of R&D

Bausch Health Welcomes Two New Members to the Executive Leadership Team

Salix in Collaboration with The U.S. Pain Foundation and the International Foundation for Gastrointestinal Disorders Establish the Inaugural Opioid-Induced Constipation (OIC) Awareness Day